SanBio, Inc. recently announced it had been granted a key patent by the United States Patent and Trademark Office covering its proprietary modified stem cells, SB623, for the treatment of retinal degeneration.
SB623 had reportedly been developed by SanBio to promote regenerative processes in the central nervous system and provide therapeutic options for debilitating neurological disorders, including retinal degeneration. United States Patent No. 9,326,999 B2 was formally granted on May 3, 2016 and covers, among other things, the use of SB623 cells in treating retinal degeneration by enhancing photoreceptor function.
Click here to read the full press release.